Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy

Figure 7

Comparison of plasma and PF IL-17A concentration in patients with ovarian cancer (a) or in the group with benign ovarian tumors (b).

(a)

(b)